These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 36008118)
1. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study. Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG J Nucl Med; 2022 Oct; 63(10):1531-1536. PubMed ID: 36008118 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. How accurate is Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066 [TBL] [Abstract][Full Text] [Related]
4. Prospective Comparison of PET Imaging with PSMA-Targeted Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492 [TBL] [Abstract][Full Text] [Related]
5. Impact of uptake time on image quality of [ van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883 [TBL] [Abstract][Full Text] [Related]
6. Pelvic lymph-node staging with Jansen BHE; Bodar YJL; Zwezerijnen GJC; Meijer D; van der Voorn JP; Nieuwenhuijzen JA; Wondergem M; Roeleveld TA; Boellaard R; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):509-520. PubMed ID: 32789599 [TBL] [Abstract][Full Text] [Related]
7. De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515 [TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574 [TBL] [Abstract][Full Text] [Related]
11. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
12. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398 [TBL] [Abstract][Full Text] [Related]
13. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168 [TBL] [Abstract][Full Text] [Related]
15. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. Caglar M; Tuncel M; Yildiz E; Karabulut E Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741 [TBL] [Abstract][Full Text] [Related]
16. Zhou J; Wu R; Wang W; Zhao Y; Liu X Hell J Nucl Med; 2022; 25(3):297-311. PubMed ID: 36576728 [TBL] [Abstract][Full Text] [Related]
17. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733 [TBL] [Abstract][Full Text] [Related]
18. Risk of metastatic disease on Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284 [TBL] [Abstract][Full Text] [Related]